Sur180 Therapeutics and Nura Health
Announce Strategic Partnership to Advance Endometriosis Care
PONCE, PUERTO RICO, March 24, 2026 /-- Sur180 Therapeutics and Nura Health announced a strategic research collaboration, approved by the Boards of both companies, designed to integrate non-invasive precision diagnostics with next-generation non-hormonal therapeutics for endometriosis.
Endometriosis affects more than 1 in 10 women of reproductive age globally, and diagnosis often takes 7–10 years, delaying access to appropriate treatment and prolonging suffering. For many patients, the condition goes far beyond a painful period — affecting work, relationships, and mental health every single day. This partnership brings together two complementary scientific strengths to accelerate solutions for earlier detection and biologically targeted treatment.
Under this agreement, Sur180 and Nura Health will coordinate research workflows, data-sharing, biomarker analytics, and exploratory clinical activities aimed at improving diagnostic accuracy and guiding treatment selection. The collaboration supports each company’s independently developed technologies, creating a unified framework where diagnostic insights and therapeutic innovation reinforce one another and enable optimized care delivery through precision medicine.
“This collaboration creates a bridge between precision diagnostics and targeted therapeutic development, allowing us to move from risk stratification and early detection to biologically informed treatment strategies,” said Idhaliz Flores, Ph.D., Co-Founder & Chair of the Scientific Board at Sur180 Therapeutics and Chief Scientific Officer at Nura Health. “At a moment when endometriosis care is shifting toward personalized medicine, aligning diagnostic insights with therapeutic innovation is both timely and transformative.”
Nura Health brings a robust multi-modal biomarker signature, deep patient subtyping and phenotyping, and precision diagnostic platform integration, while Sur180 Therapeutics contributes translational therapeutic development grounded in molecular mechanisms and preclinical evidence using novel, non-hormonal targets that have demonstrated significant benefit in reducing endometriosis lesion size and inflammation.
Co-Founder & CEO of Nura Health, Varun Kapoor, MD, emphasized the unique value of combining both teams’ expertise: “Together, we can align biological insights with targeted interventions, accelerating both rapid diagnosis and a more precise and responsive model of care for endometriosis patients that better addresses the complex disease burden across millions of affected women.”
By integrating biomarker discovery, clinical subtyping analytics, real-world data, and emerging therapeutic pathways, the partnership aims to break away from the traditional symptom-based approach. This unified effort supports a future standard of precision care defined by earlier detection, risk-informed follow-up, and mechanism-driven treatment selection.
Read the full article on AP News Here